Ambrilia says PPL-100 well-tolerated in final phase 1a study

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Ambrilia Biopharma, Inc. said the latest findings on its lead HIV protease inhibitor, PPL-100, show it to be safe and well-tolerated with a favorable pharmacokinetic profile.

Using these final clinical data, scientists conducted population pharmacokinetic modeling and pharmacokinetic-pharmacodynamic target attainment analyses, according to a company news release.

Modeling and simulation results predict a favorable steady-state pharmacokinetic profile for PPL-100, suggesting that it could be a first-line, once-daily protease inhibitor without the need of ritonavir (a boosting agent) co-administration for the treatment of both protease inhibitor-naive and experienced HIV/AIDS patients infected with highly resistant strains of the virus, the release said.

Ambrilia said these analyses also indicate that PPL-100 offers excellent "forgiveness" in the event of a missed dose, an important characteristic to address the non-adherence issues in HIV therapy.

Ambrilia is a biopharmaceutical company with headquarters in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.